The overall objective of this activity is to address the epidemiology, risk factors and key challenges in the evaluation and management of cardiovascular disease risk factors in liver transplant recipients. In particular, we will discuss practical approaches and pharmacologic considerations in the prevention and management of hypertension, dyslipidemia and diabetes in liver transplant recipients.  We will utilize a live webinar format that will be recorded for on demand viewing on Liver Learning ® .Manhal Izzy (Moderator) Dr.

Jennifer Porteous, Luca Cioccari, Paolo Ancona, Eduardo Osawa, Kelly Jones, Paul Gow, Peter Angus, Stephen Warrillow, Rinaldo Bellomo – 31 October 2018 – Acetaminophen‐induced acute liver failure (ALF) may require emergency liver transplantation (LT) in the presence of specific criteria, and its management may also include intracranial pressure (ICP) monitoring in selected patients at high risk of cerebral edema. We aimed to test the hypothesis that management of such patients without ICP monitoring or LT would yield outcomes similar to those reported with conventional management.

Kristel Mils, Laura Lladó, Emilio Ramos, Elena Escalante, Juan Fabregat – 31 October 2018

Manuela Cesaretti, Pietro Addeo, Luigi Schiavo, Rodolphe Anty, Antonio Iannelli – 31 October 2018 – The growing number of patients on waiting lists for liver transplantation and the shortage of organs have forced many centers to adopt extended criteria for graft selection, moving the limit of acceptance for marginal livers. Steatotic grafts that were, in the past, considered strictly unacceptable for transplantation because of the high risk of early nonfunction are now considered as a potential resource for organ implementation.

Pablo Ruiz, Marta Martínez‐Picola, Miguel Santana, Javier Muñoz, Sofía Pérez‐del‐Pulgar, Giorgos Koutsoudakis, Lydia Sastre, Jordi Colmenero, Gonzalo Crespo, Miquel Navasa – 30 October 2018 – The development of noninvasive biomarkers that reflect the state of immunosuppression (IS) remains an unmet need in liver transplantation (LT). Torque Teno virus (TTV) is a highly prevalent, nonpathogenic DNA virus whose plasma levels may be associated with the immune status of the host. The aim of this study was to assess the role of TTV as a biomarker of IS in LT recipients.

Carmen García‐Ruiz, José C. Fernández‐Checa – 30 October 2018 – Fatty liver disease is one of the most prevalent forms of chronic liver disease that encompasses both alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD). Alcoholic steatohepatitis (ASH) and nonalcoholic steatohepatitis (NASH) are intermediate stages of ALD and NAFLD, which can progress to more advanced forms, including cirrhosis and hepatocellular carcinoma.

Guido Stirnimann, Maryam Ebadi, Albert J. Czaja, Aldo J. Montano‐Loza – 30 October 2018 – Clinical indications for liver transplantation (LT) in patients with autoimmune hepatitis (AIH) are identical to those of patients with other chronic liver diseases that end in acute or semiacute liver failure, decompensated cirrhosis, or hepatocellular carcinoma. Recurrent disease after LT has been reported in 10%‐50% of patients with AIH, and the frequency of detection is influenced in part by the use of protocol or clinically indicated liver biopsy.

Alessandro Vitale, Fabio Farinati, Mauro Borzio, Franco Trevisani, Umberto Cllo – 30 October 2018

Graciela Elia Castro Narro, Armando Gamboa Domínguez, Alejandra Consuelo Sánchez, Abel Salazar Martínez, Jose Agramonte Hevia, J.J. Cebolla, Miguel Enrique Cuellar Mendoza, Héctor Adrián Díaz Hernández – 29 October 2018

Aysha Aslam, Rizwan Ishtiaq, Dary T.Y. Lau – 29 October 2018